延安医药二战北交所：现金流“贫血”毛利率持续承压 监管频敲警钟治理稳定性堪忧

Core Viewpoint - Shanghai Yan'an Pharmaceutical Yangpu Co., Ltd. has submitted a new application for listing on the Beijing Stock Exchange, marking its second attempt to enter the A-share market after withdrawing its initial application in September 2024 due to various concerns [1][11]. Financial Performance - From 2022 to 2024, the company's revenue increased from 323 million to 467 million, and net profit rose from 49.35 million to 84.44 million, maintaining a growth trend. However, in the first half of 2025, revenue fell by 12% year-on-year to 220 million, and net profit plummeted by 47% to 33 million, nearly halving [2][12]. - The gross margin of the main business declined from 51.04% in 2022 to 47.91% in the first half of 2025, with a significant drop of 4.59 percentage points year-on-year in 2025 [3][14]. Business Segments - The gross margin for the core formulation business decreased by 4.27% to 54.45%, while the raw material business saw a decline of 4.96% to 32.24%. Other business segments experienced a drastic drop of 41.66% [3][14]. - The company's core product, Gliclazide sustained-release tablets, successfully won bids in national centralized procurement, which provided stable market share but pressured margins due to significant price reductions [4][14]. Cash Flow and R&D Investment - The net cash flow from operating activities fluctuated significantly, with figures of 126 million, 141 million, 69.35 million, and 19.89 million, leading to a declining ratio compared to net profit. In the first half of 2025, the net cash flow was only 67% of net profit, indicating potential issues with cash flow quality [5][15]. - R&D investment has been notably insufficient, with R&D expenses decreasing from 17.04 million in 2022 to 5.52 million in the first half of 2025, and the R&D expense ratio dropping from 5.28% to 2.51% [6][17]. Supplier and Customer Concentration - The company has high supplier concentration, with the top five suppliers accounting for 77.38% to 72.84% of purchases during the reporting period, which may affect bargaining power and supply stability [7][17]. - Sales to the top five customers represented 60.25% to 63.51% of total sales, indicating a heavy reliance on a few major clients, which poses risks to business independence and resilience [8][18]. Governance and Compliance Issues - The company has faced multiple regulatory warnings for information disclosure violations, receiving four disciplinary measures from the National Equities Exchange and Quotations [9][19]. - Frequent changes in key positions, particularly the secretary of the board, have raised concerns about governance stability, reflecting underlying issues in corporate management [9][19]. - Historical issues with performance-based agreements have resulted in significant financial obligations, including cash compensation of 24.48 million due to unmet performance targets [10][20]. IPO Plans and Production Capacity - The company plans to raise 358 million through its IPO, primarily for production line construction and R&D center projects. However, the necessity of this expansion is questioned given the fluctuating capacity utilization rates [10][21]. - The production capacity utilization for tablets peaked at 127.71% in 2023, while capsule utilization was only 62.47% in the first half of 2025, indicating potential overcapacity and operational unpredictability [10][21].